Kerastem Issued Patent for Groundbreaking Hair Growth Technology

Kerastem Issued Patent for Groundbreaking Hair Growth Technology

Kerastem Hair Growth

Company has successfully completed 12-month follow-up of US Phase II clinical trial (STYLE). The Kerastem Therapy is CE mark approved for patients with alopecia in Europe

Kerastem, the global leader in the development and commercialization of regenerative medicine-based approaches to hair growth has received U.S. Patent Number 9,931,436 (the ‘436 patent).

The ‘436 patent protects the current Kerastem technology and also covers a vast array of fat, stem cell and platelet rich plasma systems and methods for hair growth.

“The issuance of our Kerastem patent by the United States Patent and Trademark Office reinforces the protectability of our novel Kerastem technology,” said Bradford A. Conlan, CEO of Kerastem.

The company recently reported 12-month top-line data from its clinical trial (STYLE), a 70 patient, phase II, US multi-center, randomized, single-blinded, and controlled study investigating Kerastem’s therapy in patients with hair loss.*

The Kerastem therapy is a one-time treatment that utilizes adipose (fat) derived regenerative cells delivered to the affected area of scalp. “The company is poised for success considering the excellent results observed from our US phase II clinical trial where a specific dose was identified that grows hair.”

About Kerastem 

Kerastem is a wholly owned subsidiary of Bimini Technologies. The Bimini portfolio also includes Puregraft (http://www.puregraft.com), the world’s leading fat transfer solution.

In 15 minutes or less, the Puregraft products provide surgeons with purified fat for reinjection and are used in hospitals and clinics around the world. The existing Puregraft customer base are ideal prospects for the new Kerastem technology.

Androgenetic Alopecia Market Size

Hair loss affects more than 40 million men and 21 million women and in the United States alone. The global hair loss treatment market generates more than $7 Billion annually and currently has limited options for men (grades I-III) and women (grades I-II) with early stage hair loss.

Source

*Source: IDE# 16488-STYLE, ClinicalTrials.gov identifier (NCT number): NCT02503852

Posted in: